Boston files PMA (premarket approval application) for Express2 stent:
This article was originally published in Clinica
Executive Summary
Boston Scientific has filed a premarket approval application with the US FDA for its Express2 stent system, which the firm plans to use as the platform for its drug-eluting stent programme. The balloon-expandable Express2 stent system combines a flexible tip with a long, low profile for easier tracking and a hydrophilic coating that is designed to reduce friction, said the Natick, Massachusetts firm. Boston expects to launch the product in the US in May, and in other markets in September this year.